Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Mereo BioPharma Group plcNASDAQ: MREO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 42.0% from a year ago
Cash & equivalents stood at $36.22M at the end of Q1 FY2026, down 42.0% from a year earlier and down 11.6% from the prior quarter. Over 3 fiscal years it compounded at -15.6% a year.
Context
- Cash & equivalents amounted to 89.2% of total assets at the end of Q1 FY2026, down 2.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -42.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 40.99M USD
- Year-over-year change
- -41.3%
- 4-year CAGR
- -24.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.99M | -41.3% |
| FY2024 | 2024-12-31 | 69.8M | +21.6% |
| FY2023 | 2023-12-31 | 57.42M | -15.8% |
| FY2022 | 2022-12-31 | 68.18M | -46.2% |
| FY2021 | 2021-12-31 | 126.75M | — |
Cash & Equivalents vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -42.0% is the 8th highest of 11, against a peer median of -2.8%.
- Cash & equivalents amounts to 89.2% of total assets for MREO, versus a peer median of 30.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $194.83M USD | +111.4% | +19.6% | 96.5% | |
| Mar 2026 | $105.42M USD | +266.1% | +210.6% | 32.3% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Dec 2025 | A$72.75M AUD | -1.5% | -5.5% | 49.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M USD | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $65M USD | +29.1% | -21.4% | 97.8% | |
| Mar 2026 | $36.22M USD | -42.0% | -15.6% | 89.2% | |
| Mar 2026 | $32.19M USD | -43.4% | +48.7% | 12.5% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $20.16M USD | -10.3% | +138.6% | 7.7% |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding MREO) | — | -2.8% | -3.1% | 30.5% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 126.75M | 68.18M | 57.42M | 69.8M | 40.99M |
| Short-term Investments | 769.47K | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 3.73M | 3.25M | 1.98M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.01M | 3.23M | 1.98M | 507K | 141K |
| Total Current Assets | 134.32M | 75.2M | 63.76M | 74.76M | 45.02M |
| Property, Plant & Equipment (Net) | 3.42M | 2.22M | 1.65M | 984K | 381K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 33.22M | 29.01M | 1.09M | 643K | 516K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 36.64M | 2.22M | 2.74M | 1.63M | 897K |
| Total Assets | 170.96M | 77.41M | 66.5M | 76.39M | 45.92M |
| Account Payables | 3.09M | 3.49M | 2.35M | 2.44M | 1.33M |
| Short-term Debt | 0 | 13.33M | 0 | 5.54M | 0 |
| Tax Payables | 0 | 0 | 662K | 770K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.6M | 1.36M | 2.37M | (413K) | 1M |
| Total Current Liabilities | 16.96M | 24.38M | 9.49M | 13.85M | 4.3M |
| Long-term Debt | 19.45M | 0 | 4.39M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13.17M | 157K | 1.18M | 1.39M | 699K |
| Total Non-current Liabilities | 34.99M | 1.64M | 6.48M | 1.57M | 699K |
| Total Liabilities | 51.95M | 26.01M | 15.96M | 15.42M | 5M |
| Common Stock | 2.37M | 2.48M | 2.78M | 3.06M | 3.14M |
| Retained Earnings | (401.6M) | (404.58M) | (419.63M) | (462.88M) | (501.02M) |
| Accumulated OCI | 183.58M | (21.69M) | (17.49M) | (18.85M) | (10.82M) |
| Other Stockholders Equity | 1 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 119.01M | 51.4M | 50.54M | 60.97M | 40.92M |
| Total Debt | 22.66M | 15.37M | 5.95M | 6.43M | 202K |
| Net Debt | (104.08M) | (52.81M) | (51.47M) | (63.37M) | (40.79M) |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.